RxDoctor Payments Data

Cecilia Berumen, APRN

Psychiatric/Mental Health · Saint Charles, ILNPI 1548621642

Payments from drug & device makers

$2,160in general payments, 2019–2025

Across 136 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$769
  • Sunovion Pharmaceuticals Inc.$374
  • Supernus Pharmaceuticals, Inc.$227
  • Takeda Pharmaceuticals U.S.A., Inc.$202
  • E.r. Squibb & Sons, L.L.C.$104
  • Johnson & Johnson$83
  • plus $401 from 11 others

What the payments were for

  • Food & beverage$2,11098%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,160 in reported general payments places this provider in the 80th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$22,678
Medicare patients
26
Services billed
1,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole19$49,770
Abilify MaintenaAripiprazole11$35,778
VraylarCariprazine Hcl15$22,751
Lurasidone Hcl31$20,682
VyvanseLisdexamfetamine Dimesylate16$6,394
Lisdexamfetamine Dimesylate13$2,740
Desvenlafaxine Succinate ErDesvenlafaxine Succinate37$2,509
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine89$2,483
AdderallDextroamphetamine/Amphetamine11$1,722
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$1,506
Bupropion XlBupropion Hcl37$1,481
Alprazolam153$1,328
Venlafaxine Hcl ErVenlafaxine Hcl95$816
Methylphenidate Hcl Er (Cd)Methylphenidate Hcl12$768
Ventolin HfaAlbuterol Sulfate11$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$36$85,54830 claims
AbbVieVraylar$769$22,75115 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Adderall$202$8,11627 claims
Almatica Pharma LLCSertraline Hcl$23$28341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Saint Charles

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →